We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
251
Shell Asset Management
Netherlands
$55M -$5.42M -186,193 -9%
OTPPB
252
Ontario Teachers' Pension Plan Board
Ontario, Canada
$54.3M -$37.9M -1,300,924 -41%
OI
253
Oakbrook Investments
Illinois
$54.1M -$204K -7,022 -0.4%
AAM
254
Advisors Asset Management
Colorado
$52.5M +$7.08M +243,317 +16%
EIM
255
ExxonMobil Investment Management
Texas
$51.7M -$2.24M -76,925 -4%
First Manhattan
256
First Manhattan
New York
$51.6M -$296K -10,183 -0.6%
WBC
257
Westpac Banking Corp
Australia
$51.3M -$1.24M -42,610 -2%
SFM
258
Systematic Financial Management
New Jersey
$51.1M +$11.6M +399,264 +29%
HCM
259
Highbridge Capital Management
New York
$50.4M +$9.73M +334,414 +24%
MIH
260
Madison Investment Holdings
Wisconsin
$49.8M -$373K -12,827 -0.7%
FIM
261
Foresters Investment Management
New York
$49.8M -$383K -13,175 -0.8%
USSCPF
262
United States Steel & Carnegie Pension Fund
New York
$49.4M
OSAM
263
O'Shaughnessy Asset Management
Connecticut
$49.1M +$17.1M +585,839 +53%
HNB
264
Huntington National Bank
Ohio
$48.6M -$226K -7,780 -0.5%
Royal London Asset Management
265
Royal London Asset Management
United Kingdom
$47.8M -$547K -18,781 -1%
MA
266
MUFG Americas
New York
$47.5M -$1.65M -56,751 -3%
OCAM
267
Onex Canada Asset Management
Ontario, Canada
$47.4M +$21.7M +744,029 +84%
ELC
268
Edgar Lomax Company
Virginia
$46.8M +$8.03M +276,043 +21%
CPSAC
269
Chas P. Smith & Associates (CPS)
Florida
$46.1M +$31M +1,065,617 +205%
SAC
270
Smith Affiliated Capital
New York
$45.9M
TAM
271
Todd Asset Management
Kentucky
$45.8M +$2.9M +99,759 +7%
MAMU
272
Marathon Asset Management (UK)
United Kingdom
$45.2M -$33.3M -1,145,562 -42%
SCM
273
Stevens Capital Management
Pennsylvania
$45.1M +$37.5M +1,288,044 +485%
ZIM
274
Zacks Investment Management
Illinois
$44.7M +$14M +482,357 +46%
MC
275
Martin Currie
United Kingdom
$44.1M +$2.47M +84,847 +6%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.